Pharma ETFs in Spotlight Following Robust Q3 Earnings Results

The third-quarter results of the broader Medical sector, which includes major large-cap pharmaceutical companies, have been quite impressive this year, with more than 82% of sector participants having reported so far. These stocks posted a solid year-over-year earnings growth scorecard of 4.3% on 10.7% revenue growth (as per our Earnings Trends report). The earnings beat ratio of 91.8% and the revenue beat ratio of 83.7% are also assuring. After factoring in actual results and projections for the companies ...